Skip to content
EveryOption

Compare care options for Major Depressive Disorder

See what we know about each option. We may not have all options. This page does not pick one for you.

Pick up to 4 care options

You can share this page. You do not need an account.

2 selected

What we found

Each option is for Major Depressive Disorder. Research and local care are different facts.

Cognitive Behavioral Therapy

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined population

NIMH Depression · checked Sep 20, 2026

Relationship: source-described CBT relationship for the Need

Statement scope

Completeness

Not assessed

Need

Major Depressive Disorder

Population

source-defined population

Source collection coverage: need:major-depressive-disorder

Pointer: /publication/treatmentExcerpt

Open source

Source: NIMH Depression. Checked Sep 20, 2026. Scope: need:major-depressive-disorder. Link: https://www.nimh.nih.gov/health/publications/depression

Research for Major Depressive Disorder

Research suggests benefit in this exact scope

Published Oct 16, 2026 · revision 3

What research says

NIMH identifies cognitive behavioral therapy as an evidence-based therapy for depression. This bounded assessment does not compare every option or determine personal suitability.

NIMH Depression · checked Oct 2, 2026

Relationship: supports bounded conclusion

Statement scope

Formulation or format

psychotherapy; in-person or virtual delivery is described generally, with no CBT-specific delivery restriction stated

Indication

depression

Need

Major Depressive Disorder

Population

people with depression; no further population or severity restriction stated

Source collection coverage: need:major-depressive-disorder

Pointer: /publication/treatmentExcerpt

Open source

Source: NIMH Depression. Checked Oct 2, 2026. Scope: need:major-depressive-disorder. Link: https://www.nimh.nih.gov/health/publications/depression

Delivery and time commitment

Canada’s CANMAT 2023 guideline for adults with major depressive disorder reports that twice-weekly CBT sessions for depression show improved outcomes compared with once-weekly sessions. This describes session frequency in the evidence the guideline reviewed; a local provider’s schedule and an individual’s needs may differ.

Official guideline documents · checked Oct 6, 2026

Relationship: supports the attributed comparison of twice-weekly with once-weekly CBT sessions

Statement scope

Formulation or format

psychological treatment sessions of CBT and IPT

Guideline

CANMAT 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults

Indication

major depressive disorder

Population

Adults with major depressive disorder covered by the CANMAT 2023 guideline

Section

Q.3.d. How Many Sessions of Psychological Treatment are Required?

Source collection coverage: global

Pointer: /document/passage/text

Open source

Source: Official guideline documents. Checked Oct 6, 2026. Scope: global. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Fluoxetine

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined study populations

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need

Statement scope

Jurisdiction

United States label

Need

Major Depressive Disorder

Population

source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Oct 16, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Research for Major Depressive Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The retained fluoxetine label reports placebo-controlled studies for major depressive disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Jurisdiction

United States label

Need

Major Depressive Disorder

Population

source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Oct 16, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Page link: https://everyoption.org/compare/major-depressive-disorder?treatments=cognitive-behavioral-therapy%2Cfluoxetine&locale=en-US